Jun Yang

Ms. Jun Yang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2020 in Bioengineering
Verified
Journal Article
Open access
PDF file
JYJun Yang
Jun Yang
Gokhan BahceciogluGokhan Bahcecioglu
Gokhan Bahcecioglu
PZPinar Zorlutuna
Pinar Zorlutuna
Emerging evidence has shown multiple roles of the tumor microenvironment (TME) components, specifically the extracellular matrix (ECM), in breast cancer development, progression, and metastasis. Aside from the biophysical properties and biochemical composition of the breast ECM, the signaling molecules are extremely important in maintaining homeostasis, and in the breast TME, they serve as the key components that facilitate tumor progression and immune evasion. Extracellular vesicles (EVs), the mediators that convey messages between the cells and their microenvironment through signaling molecules, have just started to capture attention in breast cancer research. In this comprehensive review, we first provide an overview of the impact of ECM in breast cancer progression as well as the alterations occurring in the TME during this process. The critical importance of EVs and their biomolecular contents in breast cancer progression and metastasis are also discussed. Finally, we discuss the potential biomedical or clinical applications of these extracellular components, as well as how they impact treatment outcomes.

4 February 2024 in Biomaterials
Verified
Journal Article
Closed access
JYJun Yang
Jun Yang
Gokhan BahceciogluGokhan Bahcecioglu
Gokhan Bahcecioglu
GRGeorge Ronan
George Ronan
PZPinar Zorlutuna
Pinar Zorlutuna

26 August 2025 in Current Opinion in Biomedical Engineering
Verified
Journal Article
Open access
LHLauren Hawthorne
Lauren Hawthorne
JYJun Yang
Jun Yang
PZPinar Zorlutuna
Pinar Zorlutuna
Aging is a significant cancer risk factor, yet its impact on the extracellular matrix (ECM) in tumor initiation and progression has been traditionally overlooked. While significant amounts of research focus on cellular and genetic links between aging and cancer, recent studies highlight how age-induced ECM changes create a tumor-permissive environment. Here we review this emerging research area, where age-related ECM alterations, such as age-induced increases in matrix stiffness, biochemical changes, and resultant dysregulated mechanosensitive pathways, are explored for their influence in cancer initiation and progression. Additionally, recent studies have showed how aged cells contribute to ECM alterations, further reinforcing tumor-permissive changes. This review examines both aspects of ECM aging, i.e. material-driven and cell-driven, and highlights current understandings of how ECM aging influences interactions within the tumor microenvironment in multiple cancer types, with a focus on biomechanical aspects. We also discuss emerging age-mimetic in vitro models facilitating studies of age-dependent cancer progression and therapeutic responses. Finally, we review therapeutic strategies that target aging-associated components or ECM changes to improve treatment efficacy.

16 January 2025 in Advanced Healthcare Materials
Verified
Journal Article
Open access
JYJun Yang
Jun Yang
LHLauren Hawthorne
Lauren Hawthorne
SSSharon Stack
Sharon Stack
BBBrian Blagg
Brian Blagg
AAAktar Ali
Aktar Ali
PZPinar Zorlutuna
Pinar Zorlutuna
Aging is one of the most significant risk factors for breast cancer. With the growing interest in the alterations of the aging breast tissue microenvironment, it is identified that aging is related to tumorigenesis, invasion, and drug resistance. However, current pre‐clinical disease models often neglect the impact of aging and sometimes result in worse clinical outcomes. In this study, aged animal‐generated materials are utilized to create and validate a novel age‐mimetic breast cancer model that generates an aging microenvironment for cells and alters cells toward a more invasive phenotype found in the aged environment. Furthermore, the age‐mimetic models are utilized for 3D breast cancer invasion assessment and high‐throughput screening of over 700 drugs in the FDA‐approved drug library. 36 potential effective drug targets as well as 34 potential drug targets with different drug responses in different age groups are identified, demonstrating the potential of this age‐mimetic breast cancer model for further in‐depth breast cancer studies and drug development.

1 September 2025 in bioRxiv
Verified
Preprint
Open access
LHLauren Hawthorne
Lauren Hawthorne
GBGokhan Bahcecioglu
Gokhan Bahcecioglu
JYJun Yang
Jun Yang
EHErin Howe
Erin Howe
EAEmilija Aleksandrovic
Emilija Aleksandrovic
PZPinar Zorlutuna
Pinar Zorlutuna
Aging is a key risk factor for breast cancer, yet the independent role of the extracellular matrix (ECM) in tumor progression remains understudied. Recent studies have investigated healthy mammary tissue and aging to understand their relationship; however, the independent effects of the aged ECM remain understudied. Herein, we describe a hybrid in vivo model where MCF10A ductal carcinoma (DCIS.com) cells, with or without knockdown of select targets, were seeded onto decellularized ECM from aged murine mammary glands and implanted into the mammary fat pads of young Rag1-/- mice. Knockdown of selected targets, IL1B and LOX, reduced tumor growth on aged matrices in vivo and P4HA1 knockdown enhanced tumor growth. Additionally, analysis of LOX on aged ECM highlighted LOX as a driver of tumor progression where knockdown reduced transcriptomic programs related to invasion and cellular stress. To isolate the individual ECM influence on tumor growth, MCF10A cells were seeded atop young or aged matrices where it was found that tumors grown on the aged ECM after implantation exhibited significantly greater volume and a larger tumorigenic region when compared to those from the young ECM. Furthermore, single cell RNA-sequencing revealed transcriptional enrichment of inflammatory and invasive genes within the aged matrix. Together, these results identify LOX as a driver of tumor progression and potential therapeutic target, and demonstrate that the aged ECM alone can promote breast cancer progression

12 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
GRGeorge Ronan
George Ronan
JYJun Yang
Jun Yang
PZPinar Zorlutuna
Pinar Zorlutuna
Aging is a major risk factor for cardiovascular disease, the leading cause of death worldwide, and numerous other diseases, but the mechanisms of these aging-related effects remain elusive. Recent evidence suggests that chronic changes in the microenvironment and local paracrine signaling are major drivers of these effects, but the precise effect of aging on these factors remains understudied. Here, for the first time, we directly compare extracellular vesicles obtained from young and aged patients to identify therapeutic or disease-associated agents, and directly compare vesicles isolated from heart tissue matrix (TEVs) or plasma (PEVs). While young TEVs and PEVs showed notable overlap of miRNA cargo, aged EVs differed substantially, indicating differential aging-related changes between TEVs and PEVs. TEVs overall were uniquely enriched in miRNAs which directly or indirectly demonstrate cardioprotective effects, with 45 potential therapeutic agents identified in our analysis. Both populations also showed increased predisposition to disease with aging, though through different mechanisms. Changes in PEV cargo were largely correlated with chronic systemic inflammation, while those in TEVs were more related to cardiac homeostasis and local inflammation. From this, 17 protein targets were identified which were unique to TEVs and highly correlated with aging and the onset of cardiovascular disease. Further analysis via machine learning techniques implicated several new miRNA and protein targets, independently suggesting several of the targets identified by non-machine learning analysis, which correlated with aging-related changes in TEVs. With further study, this biomarker set may serve as a powerful, potential indicator of cardiac health and age which can be measured from PEVs. Additionally, several proposed “young-enriched” therapeutic agents were validated and, when tested, could successfully prevent cell death and cardiac fibrosis in disease-like conditions.